Skip to main content
    K

    Kiora Pharmaceuticals Inc (KPRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.39
    -0.08 (-3.24%)

    Market Cap: $11.33M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(27/38)
    Avg Surprise
    -0.23%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.38
    Range$-0.38 - $-0.38
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.69+44.9%
    60d ago$-0.69+44.9%
    30d ago$-0.69+44.9%
    7d ago$-0.69+44.9%
    Current$-0.38
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.04
    Range$0.04 - $0.04
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.04---
    Sep 26EST
    		-$-0.38---
    Jun 26
    Reported Aug 7
    		$-0.34$-0.62+45.16%Beat+37.0%
    Mar 26
    Reported May 8
    		$-0.58$-0.71+18.31%Beat-11.5%
    Dec 25
    Reported Mar 25
    		$-1.73$-0.44-293.70%Miss-43.4%
    Sep 25
    Reported Nov 7
    		$0.01N/A+101.39%Beat+101.2%
    Jun 25
    Reported Aug 8
    		$-0.54$-0.58+6.90%Beat-1.9%
    Mar 25
    Reported May 9
    		$-0.52$-0.77+32.47%Beat-115.2%
    Dec 24
    Reported Mar 25
    		$-1.21$-0.74-63.19%Miss-156.9%
    Sep 24
    Reported Nov 8
    		$-0.81$-0.81+0.00%Beat+89.9%
    Jun 24
    Reported Aug 9
    		$-0.53$-0.88+39.77%Beat+92.5%
    Mar 24
    Reported May 10
    		$3.42$2.48+37.90%Beat+138.0%
    Dec 23
    Reported Mar 28
    		$-0.47$-0.42-11.90%Miss+73.3%
    Sep 23
    Reported Nov 9
    		$-8.01$-3.10-158.39%Miss+79.6%
    Jun 23
    Reported Aug 8
    		$-7.11$-9.59+25.86%Beat+89.0%
    Mar 23
    Reported May 9
    		$-9.00N/A+55.75%Beat+79.2%
    Dec 22
    Reported Mar 23
    		$-1.76$-2.46+28.46%Beat-166.7%
    Sep 22
    Reported Nov 9
    		$-39.18$-25.83-51.68%Miss+62.5%
    Jun 22
    Reported Jul 8
    		$-64.80$-72.00+10.00%Beat+48.6%
    Mar 22
    Reported Apr 15
    		$-43.20$-82.80+47.83%Beat+67.6%
    Dec 21
    Reported Mar 2
    		$-0.66$-0.30-120.00%Miss+96.8%
    Sep 21
    Reported Nov 15
    		$-104.40$-121.20+13.86%Beat+34.1%
    Jun 21
    Reported Aug 12
    		$-126.00$-150.00+16.00%Beat+7.9%
    Mar 21
    Reported May 12
    		$-133.20$-138.60+3.90%Beat-30876.7%
    Dec 20
    Reported Mar 25
    		$-20.80$-17.60-18.18%Miss+92.4%
    Sep 20
    Reported Nov 9
    		$-158.40$-151.20-4.76%Miss+61.7%
    Jun 20
    Reported Aug 6
    		$-136.80$-154.80+11.63%Beat+36.7%
    Mar 20
    Reported May 6
    		$-0.43N/AN/ABeat-100.8%
    Dec 19
    Reported Mar 4
    		$-273.60$-291.60+6.17%Beat-812.0%
    Sep 19
    Reported Nov 7
    		$-414.00$-270.00-53.33%Miss-9.5%
    Jun 19
    Reported Aug 8
    		$-216.00$-270.00+20.00%Beat+42.9%
    Mar 19
    Reported May 8
    		$54.00N/A+120.00%Beat+107.1%
    Dec 18
    Reported Mar 1
    		$-30.00$-36.00+16.67%Beat+66.7%
    Sep 18
    Reported Nov 13
    		$-378.00$-405.00+6.67%Beat+70.8%
    Jun 18
    Reported Aug 3
    		$-378.00$-702.00+46.15%Beat+75.0%
    Mar 18
    Reported May 11
    		$-756.00$-1269.00+40.43%Beat+50.0%
    Dec 17
    Reported Mar 2
    		$-90.00$-144.00+37.50%Beat+60.5%
    Sep 17
    Reported Nov 14
    		$-1296.00$-1170.00-10.77%Miss-
    Jun 17
    Reported Aug 4
    		$-1512.00$-1044.00-44.83%Miss-
    Mar 17
    Reported May 5
    		$-1512.00$-1962.00+22.94%Beat-
    Dec 16
    Reported Feb 23
    		$-228.00$-254.00+10.24%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.90EV/EBITDAN/A
    Price/FCF-1.71xFCF Yield-58.34%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-56.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage206.49x
    Current Ratio8.97xQuick Ratio8.97x
    Trading Statistics
    Beta-0.21Avg Volume14.45K
    52-Week High$2.9152-Week Low$1.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.51
    SMA 20$2.58
    SMA 50$2.59
    SMA 200$2.41
    EMA 10$2.50
    EMA 20$2.54
    EMA 50$2.57
    EMA 200$2.51

    MACD

    Line: -0.04Signal: -0.02Hist: -0.02

    ADX

    ADX: 20.0+DI: 18.5-DI: 25.1

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down100.0
    PSAR$2.58

    Bollinger Bands

    Upper Band$2.76
    Lower Band$2.40
    %B Position1410%(Upper)
    Band Width-0.02

    RSI (14-Day)

    Neutral
    34.3

    Momentum Oscillators

    Stoch %K7.2
    Stoch %D12.1
    Williams %R-87.5
    ROC (10d)-7.4%
    Momentum-0.19
    CCI (20d)-170.1
    MFI (14d)35.7

    Volatility Measures

    ATR (14d)$0.08(3.4%)
    StdDev (20d)0.09
    Hist Vol31.1%(Moderate)

    Volume Flow

    VWAP$2.41
    OBV50.5M
    AD Line-15.1M
    CMF (20d)0.146

    Volume Metrics

    Avg Vol (20d)13.5K
    Vol Ratio1.9x(High)
    VWMA (20d)$2.59

    Pivot Points

    R3$2.53
    R2$2.51
    R1$2.49
    Pivot Point$2.47
    S1$2.45
    S2$2.43
    S3$2.41

    Advanced Oscillators

    TSI-13.29
    Ultimate Osc43.0
    KST-34.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$-15,951,822$0$20,000$16.00M$283,872$0
    Cost of Revenue$0$0$10,508$0$0$0$34,089$0$0$0$7,935$0
    Gross Profit$0$0$-10,508$0$0$0$-15,985,911$0$20,000$16.00M$-7,935$0
    Operating Expenses$2.21M$2.51M$7.31M$794,437$2.40M$2.33M$2.56M$3.60M$2.56M$2.78M$2.12M$5.92M
    R&D$2.08M$2.12M$2.93M$2.73M$2.59M$2.53M$1.92M$2.18M$2.05M$1.68M$1.11M$1.09M
    SG&A$1.38M$1.61M$1.46M$1.44M$1.35M$1.49M$1.33M$1.38M$1.54M$1.30M$880,550$1.42M
    Operating Income$-2,213,771$-2,510,195$-7,310,085$-794,437$-2,396,196$-2,330,354$-2,564,682$-3,602,237$-2,544,887$13.22M$-2,118,649$-5,918,568
    Interest Income$146,232$139,338$190,310$201,822$225,237$276,633$438,860$248,840$342,102$223,047$0$49,912
    Interest Expense$0$0$0$0$0$0$0$0$0$0$59,638$0
    Income Before Tax$-2,079,010$-2,417,984$-7,166,490$-616,323$-2,264,516$-2,069,974$-2,158,497$-3,413,326$-2,221,646$13.45M$-2,178,287$-5,762,941
    Income Tax Expense$0$0$-649,969$-643,129$-112,057$123,006$2.07M$0$0$0$0$0
    Net Income$-2,079,010$-2,417,984$-6,516,521$26,806$-2,152,459$-2,192,980$-4,223,502$-3,413,326$-2,221,646$13.45M$-2,268,606$-5,762,941
    EBITDA$-2,214,501$-2,546,759$-7,326,332$-807,593$-2,486,330$-2,346,289$-2,569,999$-3,660,071$-2,557,419$13.24M$-2,204,745$-5,801,545
    EBIT$-2,225,242$-2,557,322$-7,336,840$-818,145$-2,489,753$-2,346,607$-2,575,911$-3,662,166$-2,563,748$13.23M$-2,212,680$-5,812,853
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KPRX

    News

    Kiora Pharmaceuticals Q3 2026 Earnings Date and Estimates

    Kiora Pharmaceuticals (NASDAQ:KPRX) is expected to report its Q3 2026 earnings on Friday, November 6, 2026, before the market opens...

    MarketBeat•10/11/26•Neutral

    Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Stock Price, News & Analysis

    Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) is a clinical-stage pharmaceutical company focused on developing therapies for ophthalmic diseases, with lead product KIO-301 in Phase 2 trials for retinitis pigmentosa...

    kalkine.ca•9/29/26•Neutral

    New investor crosses 5% ownership in Kiora Pharmaceuticals (NASDAQ: KPRX)

    Baslake Partners and its affiliates have reported a 5.8% beneficial ownership stake in Kiora Pharmaceuticals (KPRX)...

    Stock Titan•9/18/26•Neutral

    Kiora Pharmaceuticals names Keith Lane clinical development head

    Kiora Pharmaceuticals (NASDAQ:KPRX) has appointed Keith J. Lane as Executive Vice President of Clinical Development and Regulatory Affairs. Lane brings over two decades of experience in ophthalmic drug development...

    Investing.com•9/8/26•Bullish

    Kiora Pharmaceuticals names Keith Lane clinical development head By Investing.com

    Kiora Pharmaceuticals has appointed Keith J. Lane as Executive Vice President of Clinical Development and Regulatory Affairs. Lane brings over two decades of experience in ophthalmic drug development...

    Investing.com Nigeria•9/8/26•Bullish

    KPRX Valuation and Fair Value

    P/E
    -0.9x
    Forward P/E
    2.4x
    P/FCF
    -1.7x
    P/B
    0.9x
    See GNG's fair value

    KPRX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -56.4%
    FCF yield
    -58.3%

    KPRX Competitors

    CompanyTicker
    Alaunos Therapeutics IncTCRT
    Ensysce Biosciences IncENSC
    Tempest Therapeutics IncTPST
    Phio Pharmaceuticals CorpPHIO
    Intensity Therapeutics, Inc. Common stockINTS
    Cytosorbents CrpCTSO
    Passage Bio IncPASG
    NLS Pharmaceutics AGNLSP

    Sector: Healthcare

    KPRX Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    -19.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.38
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About KPRX

    Does KPRX pay dividends?

    Kiora Pharmaceuticals Inc (KPRX) does not currently pay a regular dividend.

    What is KPRX's market cap?

    Kiora Pharmaceuticals Inc (KPRX) has a market capitalization of $11.33M with a current stock price of $2.39.

    Related stocks

    Sector: Healthcare

    All stocks starting with K

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In